The future challenges facing the development of new antimicrobial drugs.
about
The Mycobacterium tuberculosis Rv2540c DNA sequence encodes a bifunctional chorismate synthaseTargeting antibacterial agents by using drug-carrying filamentous bacteriophagesIn vitro and in vivo antimicrobial activity of granulysin-derived peptides against Vibrio choleraeTargeted drug-carrying bacteriophages as antibacterial nanomedicinesTotal synthesis of lysobactinNanoparticles: Alternatives Against Drug-Resistant Pathogenic MicrobesDermatophytic defensin with antiinfective potentialA new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infectionsImproved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infectionTargeting an Essential GTPase Obg for the Development of Broad-Spectrum AntibioticsAntagonists of Hsp16.3, a low-molecular-weight mycobacterial chaperone and virulence factor, derived from phage-displayed peptide librariesThe methymycin/pikromycin pathway: a model for metabolic diversity in natural product biosynthesisNew tricks of well-known aminoazoles in isocyanide-based multicomponent reactions and antibacterial activity of the compounds synthesized.δ-Carbolines and their ring-opened analogs: synthesis and evaluation against fungal and bacterial opportunistic pathogensMedium effects on minimum inhibitory concentrations of nylon-3 polymers against E. coli.Effects of antibacterial mineral leachates on the cellular ultrastructure, morphology, and membrane integrity of Escherichia coli and methicillin-resistant Staphylococcus aureus.Deletion mutations conferring substrate spectrum extension in the class A β-lactamase.Total synthesis and biological evaluation of the antibiotic lysocin E and its enantiomeric, epimeric, and N-demethylated analogues.Platforms for antibiotic discovery.Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.Novel classes of antibiotics or more of the same?Control of bacterial persister cells by Trp/Arg-containing antimicrobial peptides.The effects of marine carbohydrates and glycosylated compounds on human health.Synthesis, biological evaluation and 2D-QSAR study of halophenyl bis-hydrazones as antimicrobial and antitubercular agents.Virtual drug discovery and development for neglected diseases through public-private partnerships.Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.Neomycin Sulfate Improves the Antimicrobial Activity of Mupirocin-Based Antibacterial Ointments.Enhancing the utility of existing antibiotics by targeting bacterial behaviour?Antibiotic resistance in Staphylococcus aureus: concerns, causes and cures.Can virulence factors be viable antibacterial targets?Gram (-) microorganisms DNA polymerase inhibition, antibacterial and chemical properties of fruit and leaf extracts of Sorbus acuparia and Sorbus caucasica var. yaltirikii.Dual action antimicrobials: nitric oxide release from quaternary ammonium-functionalized silica nanoparticles.Novel approaches to developing new antibiotics for bacterial infections.Targeting bacterial membrane function: an underexploited mechanism for treating persistent infectionsIdentification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa.DCAP: a broad-spectrum antibiotic that targets the cytoplasmic membrane of bacteria.Increased multi-drug resistant Escherichia coli from hospitals in Khartoum state, SudanRisks of long-term catheterization in the community--and managing them.Safety in urine sampling: maintaining an infection-free environment.A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.
P2860
Q21284384-B7284060-4801-4E9F-A66D-02EDFFC96EADQ24548258-C95D9E20-24E7-4A5F-8C89-A40E39C15097Q24647817-D39B159D-0A44-4FA0-8FD3-366D03FD1ABDQ24673452-37FCE39E-0321-4721-B28D-FB542E4880EFQ24684181-ED00A757-2248-4A57-967E-CA8805473458Q26746108-8FA37FAC-B0FF-4613-B9DD-50E7CA505F5FQ27679095-AAA590E2-8001-4856-BC69-0903676E937DQ28474929-F932BC09-363B-4F83-8ED1-6BCC584DEB91Q28486312-9DE33582-5FDD-43F6-B99A-7F8C2F44F86DQ28553171-E5D3C4AE-4836-4E0B-A8D3-47B31A569878Q33226580-47B5BE78-FDE6-4819-A417-7C664F86CE5EQ33746324-97E10C61-E3C0-446E-90B4-53FACB2938B5Q33824188-6640F9A4-528D-43FA-99A0-94A2BFFB8FCAQ33860971-7A0357C8-F235-4C23-95CF-ECDDA037463AQ34083620-38521F99-0C17-4E66-BAEF-0376D844E9CFQ34174234-221C5BC6-3643-4BBC-A077-C58CD471105EQ34299058-C91843AB-2E2E-4895-B934-C1A830C32354Q34667080-EBA6FF72-6170-40B8-BDA4-66F36FC14C2EQ34694926-6F03CC1E-CC33-43D7-8913-8D1C8A1C2614Q34823019-3E9EEF93-AA56-46C5-A9F1-C25A4B1CDF95Q34903245-4194DB83-F140-440B-94B1-0710A08369E0Q35138938-C87A2E7F-8E66-462D-9408-165C7C1B1602Q35381522-34645857-BD79-412B-966A-E1A94C9C7F53Q35585730-42E004E5-0439-43AF-925D-6DF6C4107481Q35605447-CFCED192-32BF-4FBF-B083-A9917E4578F1Q35758962-8E3DE5EE-C8A9-4531-A6C4-81D208644A1EQ35848987-D93231DB-7826-4817-91CC-9A479A3FD68DQ35853204-348A9B19-F682-4B42-A7BB-582C4E15515FQ35917130-0227C3AB-3929-4BE8-9EBD-B747631998FBQ35917322-C9EF8EC2-00F7-4CA5-A8DA-38F12ACB5E0EQ36196663-0A320D1A-2FD6-45B7-BCC6-04BBC44A9FD1Q36352429-4D02C440-B16A-4C51-99D9-7E9CBC45831BQ36358643-E5925328-BA41-421B-9AED-38402957F78CQ36393640-F1FBB5EA-0BA0-42D9-B1AD-47C961E79435Q36409828-B6D3A88F-B8A2-4E44-B6B1-DCD7AB0C39A6Q36451806-FF82EC54-CCF7-4A39-8C82-7B4CF646CC67Q36569808-95A18456-515B-4B41-991B-006905AF5FA0Q36640832-EB6A7455-0A14-4464-851C-C64ECE44772CQ36654852-1807659C-88CD-4657-B7C4-64DBE8D0FD60Q36684146-354476F6-2332-4D3B-8063-CB7BAB51FBCB
P2860
The future challenges facing the development of new antimicrobial drugs.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The future challenges facing the development of new antimicrobial drugs.
@ast
The future challenges facing the development of new antimicrobial drugs.
@en
The future challenges facing the development of new antimicrobial drugs.
@nl
type
label
The future challenges facing the development of new antimicrobial drugs.
@ast
The future challenges facing the development of new antimicrobial drugs.
@en
The future challenges facing the development of new antimicrobial drugs.
@nl
prefLabel
The future challenges facing the development of new antimicrobial drugs.
@ast
The future challenges facing the development of new antimicrobial drugs.
@en
The future challenges facing the development of new antimicrobial drugs.
@nl
P2093
P356
P1476
The future challenges facing the development of new antimicrobial drugs
@en
P2093
Anthony Coates
Richard Bax
P2888
P304
P356
10.1038/NRD940
P577
2002-11-01T00:00:00Z